Amylyx Pharmaceuticals, Inc. (AMLX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Amylyx Pharmaceuticals, Inc. reported revenue of $0, down 100.0% from the prior year. The company ran a net loss. It held $332.64M in total assets against $27.39M in total liabilities.
Key ratios (FY2025)
-47.4%
Return on equity
-100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $87.37M | $380.79M | $22.23M | — | — |
| Cost of Revenue | $0 | $5.95M | $25.44M | $2.99M | — | — |
| Operating Income | -$153.29M | -$314.73M | $38.80M | -$201.34M | -$82.69M | — |
| Net Income | -$144.74M | -$301.74M | $49.27M | -$198.38M | -$87.93M | — |
| EPS (Diluted) | $-1.53 | $-4.43 | $0.70 | $-3.39 | $-13.35 | — |
| Total Assets | $332.64M | $193.63M | $517.45M | $391.45M | $105.61M | — |
| Total Liabilities | $27.39M | $28.87M | $84.02M | $50.85M | $17.43M | — |
| Shareholders' Equity | $305.26M | $164.76M | $433.43M | $340.61M | -$151.17M | -$66.72M |
| Cash & Equivalents | $226.65M | $77.39M | $170.20M | $62.53M | $50.19M | — |
| Operating Cash Flow | -$123.34M | -$167.65M | $11.92M | -$179.87M | -$74.80M | — |
| Capital Expenditures | $138.0K | $157.0K | $1.24M | $2.53M | $353.0K | — |
| Shares Outstanding | 109.88M | 68.63M | 67.71M | 66.51M | 7.02M | — |